AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AT-0174’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AT-0174 overview
AT0174 is under development for the treatment of solid tumors including non-small cell lung carcinoma, small-cell lung cancer, triple-negative breast cancer, malignant melanoma, gastroesophageal junction carcinoma, esophageal squamous cell cancer, metastatic colorectal cancer, epithelial ovarian cancer, endometrial cancer, thyroid cancer, oligodendroglioma, anaplastic astrocytoma, glioblastoma multiforme (GBM) . The drug candidate acts by targeting indoleamine 2,3 dioxygenase 1 (IDO1) and tryptophan 2,3 dioxygenase (TDO2). It is administered through oral route as a capsule.
Antido Therapeutics (Australia) overview
Antido Therapeutics (Australia) is a biotechnology company that focuses on clinical trials in the fields of solid tumors, and other unmet medical needs. The company is headquartered in Melbourne, Victoria, Australia.
For a complete picture of AT-0174’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
